View Item 

Show simple item record

P neumocystis jirovecii pneumonia is rare in renal transplant recipients receiving only one month of prophylaxis
dc.contributor.authorAnand, S.en_US
dc.contributor.authorSamaniego, Millie D.en_US
dc.contributor.authorKaul, D. R.en_US
dc.date.accessioned2012-01-05T22:05:12Z
dc.date.available2013-02-01T20:26:12Zen_US
dc.date.issued2011-12en_US
dc.identifier.citationAnand, S.; Samaniego, M.; Kaul, D.R. (2011). " P neumocystis jirovecii pneumonia is rare in renal transplant recipients receiving only one month of prophylaxis." Transplant Infectious Disease 13(6): 570-574. <http://hdl.handle.net/2027.42/89470>en_US
dc.identifier.issn1398-2273en_US
dc.identifier.issn1399-3062en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/89470
dc.publisherWiley Periodicals, Inc.en_US
dc.subject.otherP Neumocystis Jirovecii Pneumoniaen_US
dc.subject.otherPCPen_US
dc.subject.otherN Ocardiaen_US
dc.subject.otherRenal Transplantationen_US
dc.subject.otherTrimethoprim–Sulfamethoxazoleen_US
dc.titleP neumocystis jirovecii pneumonia is rare in renal transplant recipients receiving only one month of prophylaxisen_US
dc.typeArticleen_US
dc.rights.robotsIndexNoFollowen_US
dc.subject.hlbsecondlevelMedicine (General)en_US
dc.subject.hlbsecondlevelMicrobiology and Immunologyen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.identifier.pmid22093215en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/89470/1/tid692.pdf
dc.identifier.doi10.1111/j.1399-3062.2011.00692.xen_US
dc.identifier.sourceTransplant Infectious Diseaseen_US
dc.identifier.citedreferenceFishman JA. Prevention of infection caused by Pneumocystis carinii in transplant recipients. Clin Infect Dis 2001; 33 ( 8 ): 1397 – 1405.en_US
dc.identifier.citedreferenceMartin SI, Fishman JA. Pneumocystis pneumonia in solid organ transplant recipients. Am J Transplant 2009; 9 ( Suppl 4 ): S227 – S233.en_US
dc.identifier.citedreferenceEBPG Expert Group on Renal Transplantation. European best practice guidelines for renal transplantation. Section IV: Long‐term management of the transplant recipient. IV.7.1 Late infections. Pneumocystis carinii pneumonia. Nephrol Dial Transplant 2002; 17 ( Suppl 4 ): 36 – 39.en_US
dc.identifier.citedreferenceClark NM. Nocardia in solid organ transplant recipients. Am J Transplant 2009; 9 ( Suppl 4 ): S70 – S77.en_US
dc.identifier.citedreferenceGordon SM, LaRosa SP, Lamadi S, et al. Should prophylaxis for Pneumocystis carinii pneumonia in solid organ transplant recipients ever be discontinued? Clin Infect Dis 1999; 28 ( 2 ): 240 – 246.en_US
dc.identifier.citedreferenceNeff RT, Jindal RM, Yoo DY, Hurst FP, Agodoa LY, Abbott KC. Analysis of USRDS: incidence and risk factors for Pneumocystis jiroveci pneumonia. Transplantation 2009; 88 ( 1 ): 135 – 141.en_US
dc.identifier.citedreferencePeleg AY, Husain S, Qureshi ZA, et al. Risk factors, clinical characteristics, and outcome of Nocardia infection in organ transplant recipients: a matched case‐control study. Clin Infect Dis 2007; 44 ( 10 ): 1307 – 1314.en_US
dc.identifier.citedreferenceBatiuk TD, Bodziak KA, Goldman M. Infectious disease prophylaxis in renal transplant patients: a survey of US transplant centers. Clin Transplant 2002; 16 ( 1 ): 1 – 8.en_US
dc.identifier.citedreferenceArend SM, Westendorp RG, Kroon FP, et al. Rejection treatment and cytomegalovirus infection as risk factors for Pneumocystis carinii pneumonia in renal transplant recipients. Clin Infect Dis 1996; 22 ( 6 ): 920 – 925.en_US
dc.identifier.citedreferenceRadisic M, Lattes R, Chapman JF, et al. Risk factors for Pneumocystis carinii pneumonia in kidney transplant recipients: a case‐control study. Transpl Infect Dis 2003; 5 ( 2 ): 84 – 93.en_US
dc.identifier.citedreferencede Boer MG, Bruijnesteijn van Coppenraet LE, Gaasbeek A, et al. An outbreak of Pneumocystis jiroveci pneumonia with 1 predominant genotype among renal transplant recipients: interhuman transmission or a common environmental source? Clin Infect Dis 2007; 44 ( 9 ): 1143 – 1149.en_US
dc.identifier.citedreferenceGianella S, Haeberli L, Joos B, et al. Molecular evidence of interhuman transmission in an outbreak of Pneumocystis jirovecii pneumonia among renal transplant recipients. Transpl Infect Dis 2010; 12 ( 1 ): 1 – 10.en_US
dc.identifier.citedreferenceRabodonirina M, Vanhems P, Couray‐Targe S, et al. Molecular evidence of interhuman transmission of Pneumocystis pneumonia among renal transplant recipients hospitalized with HIV‐infected patients. Emerg Infect Dis 2004; 10 ( 10 ): 1766 – 1773.en_US
dc.identifier.citedreferenceSchmoldt S, Schuhegger R, Wendler T, et al. Molecular evidence of nosocomial Pneumocystis jirovecii transmission among 16 patients after kidney transplantation. J Clin Microbiol 2008; 46 ( 3 ): 966 – 971.en_US
dc.identifier.citedreferenceYazaki H, Goto N, Uchida K, Kobayashi T, Gatanaga H, Oka S. Outbreak of Pneumocystis jiroveci pneumonia in renal transplant recipients: P. jiroveci is contagious to the susceptible host. Transplantation 2009; 88 ( 3 ): 380 – 385.en_US
dc.identifier.citedreferenceFox BC, Sollinger HW, Belzer FO, Maki DG. A prospective, randomized, double‐blind study of trimethoprim‐sulfamethoxazole for prophylaxis of infection in renal transplantation: clinical efficacy, absorption of trimethoprim‐sulfamethoxazole, effects on the microflora, and the cost‐benefit of prophylaxis. Am J Med 1990; 89 ( 3 ): 255 – 274.en_US
dc.identifier.citedreferenceHibberd PL, Tolkoff‐Rubin NE, Doran M, et al. Trimethoprim‐sulfamethoxazole compared with ciprofloxacin for the prevention of urinary tract infection in renal transplant recipients. A double‐blind, randomized controlled trial. Online J Curr Clin Trials 1992 Aug 11, Doc No 15.en_US
dc.identifier.citedreferenceOz HS, Hughes WT. Novel anti‐ Pneumocystis carinii effects of the immunosuppressant mycophenolate mofetil in contrast to provocative effects of tacrolimus, sirolimus, and dexamethasone. J Infect Dis 1997; 175 ( 4 ): 901 – 904.en_US
dc.identifier.citedreferencePlacebo‐controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. European Mycophenolate Mofetil Cooperative Study Group. Lancet 1995; 345 ( 8961 ): 1321 – 1325.en_US
dc.identifier.citedreferenceA blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. Transplantation 1996; 61 ( 7 ): 1029 – 1037.en_US
dc.identifier.citedreferenceSollinger HW. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. U.S. Renal Transplant Mycophenolate Mofetil Study Group. Transplantation 1995; 60 ( 3 ): 225 – 232.en_US
dc.identifier.citedreferencePonce CA, Gallo M, Bustamante R, Vargas SL. Pneumocystis colonization is highly prevalent in the autopsied lungs of the general population. Clin Infect Dis 2010; 50 ( 3 ): 347 – 353.en_US
dc.identifier.citedreferenceCalderón EJ. Pneumocystis infection: seeing beyond the tip of the iceberg. Clin Infect Dis 2010; 50 ( 3 ): 354 – 356.en_US
dc.identifier.citedreferenceKotton CN, Lattes R. Parasitic infections in solid organ transplant recipients. Am J Transplant 2009; 9 ( Suppl 4 ): S234 – S251.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
tid692.pdf
Size:
79.35KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.